TQB3616 + itraconazole

TQB3616 + itraconazole is a combination of two pharmaceutical agents. TQB3616 is a novel, orally administered small molecule inhibitor that selectively targets cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6). By inhibiting CDK4/6, TQB3616 blocks phosphorylation of the retinoblastoma protein (Rb), preventing cell cycle progression from G1 to S phase and leading to cell cycle arrest in tumor cells. It has demonstrated potent antiproliferative activity in hormone receptor-positive breast cancer models and shows synergistic effects when combined with endocrine or HER2-targeted therapies[1][2][5][7]. Itraconazole is an established antifungal agent that inhibits fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes. The combination may be used in clinical pharmacokinetic studies to assess drug-drug interactions or safety profiles.